Fossil Group, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
In connection with the appointments of Carriero effective February 12, 2025, Martin effective February 17, 2025, and Greben effective March 17, 2025, the Company is granting Carriero an employment inducement award consisting of 100,000 time-based restricted stock units ('RSUs'), Martin an employment inducement award consisting of 129,581 RSUs and Greben an employment inducement award consisting of 150,000 RSUs.
All three grants have an effective grant date of April 15, 2025 (the 'Grant Date'). The RSUs will vest one third on the first, second and third anniversaries, respectively, of the Grant Date, subject to each officer's continuous employment with the Company on each vesting date.
The inducement awards to Carriero, Martin and Greben were granted as a material inducement to their employment and were approved by the Company's Compensation and Talent Management Committee on March 4, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards were granted outside the Company's equity incentive plan.
About Fossil Group, Inc.
Fossil Group, Inc. is a global design, marketing, distribution and innovation company specializing in lifestyle accessories. Under a diverse portfolio of owned and licensed brands, our offerings include watches, jewelry, handbags, small leather goods, belts and sunglasses. We are committed to delivering the best in design and innovation across our owned brands, Fossil, Michele, Relic, Skagen and Zodiac, and licensed brands, Armani Exchange, Diesel, Emporio Armani, kate spade new york, Michael Kors and Tory Burch. We bring each brand story to life through an extensive distribution network across numerous geographies, categories, and channels. Certain press release and SEC filing information concerning the Company is also available at www.fossilgroup.com.
Global Corporate Communications:
James Webb
Fossil Group
[email protected]
Investor Relations:
Christine Greany
The Blueshirt Group
[email protected]
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
AskNewt Unveils Version 3.0, Bringing Trusted, Accurate, Smarter, Faster, and More Personalized AI Insights to Finance and Everyday Life
The latest release introduces real-time, context-aware analysis, secure portfolio tools, and persistent memory — delivering sharper answers and a safer, more personalized user experience. NEW YORK, Aug. 20, 2025 /PRNewswire/ -- AskNewt, a leading provider of AI-powered financial and personal insights, today announced the upcoming release of AskNewt Version 3.0, the company's most advanced platform update to date. Built on direct feedback from its growing user community, AskNewt 3.0 introduces powerful new features designed to enhance accuracy, speed, and personalization across financial research, decision-making, and everyday use. "AskNewt 3.0 represents a major step forward in how individuals and professionals can leverage AI for timely, accurate, and actionable insights," Chief AI Officer Abbas Shah said, adding that "Our goal is to deliver a smarter and safer AI assistant that not only answers questions, but also anticipates user needs, learns preferences, and supports critical decision-making in real time." Key Features of AskNewt 3.0: Sharper Answers, Faster – Advanced parsing of financial and general queries powered by the latest large language models. Real-Time, Context-Aware Insights – Information and analysis that reflect current events and market conditions. Personalized Experience – Persistent memory that adapts to each user's profile, interests, and history. Smarter Financial Tools – Secure portfolio uploads with real-time performance tracking and instant stock analysis. Everyday Intelligence – Expanded support for trip planning, restaurant booking, shopping deals, and more. Streamlined Interface – A cleaner, more focused design for seamless user experience. Continuous Self-Improvement – A system that learns and improves with each engagement. Private by Design – Strict commitment to data privacy, with no sharing of user information with third parties. About AskNewtNew York-based AskNewt, LLC has developed AskNewt, an AI Agentic search engine built for sharper, faster answers—especially for financial and complex queries. It delivers real-time, context-aware insights with verified accuracy, a streamlined interface, and personalized results that improve over time. Private by design and free to use, AskNewt aims to reach 15–20 million users in two years, following a proven B2C growth and monetization model. Download the mobile apps here for AskNewt: Apple Store link Google Play link View original content to download multimedia: SOURCE AskNewt, LLC
Yahoo
22 minutes ago
- Yahoo
Larkspur Biosciences Announces Discovery of LRK-4189, a First-in-Class Degrader of the Lipid Kinase PIP4K2C, for the Treatment of Microsatellite Stable (MSS) Colorectal Cancer at the ACS Fall 2025 Meeting
First-in-human, Phase 1 Study of LRK-4189 to Begin in the Fourth Quarter CAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a company pioneering a new wave in cancer therapy that destroys tumors by targeting cancer cell fitness, today announced the discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of microsatellite stable (MSS) colorectal cancer (CRC) and other solid tumors. The announcement was made at a presentation Larkspur was invited to give at the prestigious MEDI First Time Disclosures: Breakthroughs on New Medicines session at ACS Fall 2025, a meeting of the American Chemical Society in Washington, DC. Cancer cells maintain their fitness by developing survival adaptations that foster escape from intrinsic and extrinsic mechanisms of cell death in conditions of stress. Phosphatidylinositol 5-phosphate 4-kinase, type II, gamma (PIP4K2C) is a lipid kinase associated with poor outcomes in a range of cancers including CRC and breast cancers. PIP4K2C is co-opted by cancer cells to increase their fitness by evading immune surveillance and adapting to stress. 'Genetic studies have long highlighted PIP4K2C as a key player in cancer stress adaptation, but its extremely low kinase activity made it resistant to conventional inhibition approaches,' said Catherine Sabatos-Peyton, PhD, CEO of Larkspur Biosciences. 'With our novel degrader, LRK-4189, we've finally unlocked this critical pathway. By reducing cancer cell fitness, triggering intrinsic apoptosis, and engaging the immune system to clear residual tumor cells, LRK-4189 has the potential to overcome the limitations of earlier therapies. We're excited to advance this promising therapy to the clinic later this year.' According to the American Cancer Society, in the United States, approximately 150,000 cases of CRC are diagnosed annually, with MSS CRC accounting for about 85% of all CRC cases. About LRK-4189 LRK-4189 is an orally bioavailable, selective degrader of PIP4K2C with subnanomolar potency in primary human cells. LRK-4189-mediated degradation of PIP4K2C leads to intrinsic cancer cell death and activates interferon signaling, triggering multiple killing mechanisms in difficult-to-treat MSS CRC cells. In vivo, LRK-4189 demonstrates dose dependent PKPD with single agent efficacy in multiple models of CRC and synergy with first-line standard of care chemotherapy. In primary human CRC patient-derived spheroids, 50% of patient samples respond to LRK-4189 with a preferential response in MSS CRC, which compares favorably to benchmark cetuximab in the same platform (35%). Cetuximab may be either a first- or second-line treatment in people with RAS wild type CRC. LRK-4189 has completed IND-enabling studies and expects to initiate a Phase 1 clinical trial in Q4 2025. About Larkspur Biosciences Larkspur Biosciences is pioneering a new wave in cancer therapy that destroys tumors by targeting cancer cell fitness. Larkspur develops therapies that decrease cancer cell fitness and sensitizes the cells to intrinsic and immune-driven mechanisms of killing. The company is advancing first-in-class programs that target the adaptations cancer cells use to proliferate, invade tissue, and escape the immune system. LarkX, the company's proprietary bioinformatics platform, couples machine learning with tumor genetics to discover cancer cell fitness pathways that originate in the tumor and enrich clinical strategies for potential responders to its therapies across multiple types of cancer. Larkspur's founders include Lewis C. Cantley, PhD, professor of medicine at Dana-Farber Cancer Institute, professor of cell biology at Harvard Medical School; Vijay K. Kuchroo, DVM, PhD, professor of neurology at Harvard Medical School, senior scientist at Brigham and Women's Hospital; and Nathanael Gray, PhD, professor of chemical and systems biology at Stanford University. Visit us at and follow us on LinkedIn and X. Media Contact:Dan BoyleScientPRdan@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Steep Hill Announces Appointment of Director
Toronto, Ontario--(Newsfile Corp. - August 20, 2025) - Steep Hill Inc. (CSE: STPH) ("Steep Hill" or the "Company") is pleased to announce that Ms. Sonia Agustina has been appointed as a Director of the Company, effective August 13, 2025. Ms. Agustina is a Chartered Professional Accountant with over 20 years of financial leadership experience in both public practice and industry, specializing in regulated, high-growth, and publicly listed companies. She currently serves as Chief Financial Officer of Galleon Gold Corp., a TSXV-listed exploration company, where she oversees all aspects of financial strategy, regulatory reporting, and treasury operations. Through her advisory practice, she has supported numerous early-stage and public companies on IPO readiness, M&A, financial compliance, and corporate restructuring. Her industry experience spans mineral resources, cannabis, technology and manufacturing. Sonia is a Chartered Professional Accountant (Ontario) and holds a Bachelor of Administrative Studies (Honours) from York University. In addition, the Company wishes to announce that it has granted an aggregate of 1,300,000 options to purchase common shares of the Company to directors, officers and consultants of the Company, exercisable at a price of $0.065 per common share for a period of five (5) years from the date of grant, in accordance with the terms of the Company's stock option plan. The common shares issuable upon exercise of the options are subject to a statutory hold period of four months and one day from the date of grant. For more information, contact: Sameet Kanade, CEOEmail: 647-876-6525 Cautionary Note Regarding Forward-Looking Statements Certain information contained herein may constitute forward-looking statements that involve risks and uncertainties. Readers are cautioned not to place undue reliance on forward-looking statements, including, but not limited to, statements regarding the anticipated completion of the transactions described herein. Factors that could cause actual results to vary from forward-looking statements or may affect the operations, performance, development, and results of the Company's business. The forward-looking statements contained in this news release are made as of the date of this news release, and, except to the extent required by applicable law, the Company assumes no obligation to update or revise forward-looking statements made herein or otherwise, whether because of new information, future events, or otherwise. The forward-looking statements contained in this news release are expressly qualified by this cautionary note. The Canadian Securities Exchange (CSE) has not reviewed, approved, or disapproved the contents of this press release. To view the source version of this press release, please visit Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
